Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19768620 | 1.00 | EPHX1 (0.33) | EPHX1BTKMIFKMT2AL3MBTL1 | |
| SCHEMBL19768621 | 0.94 | MIF (0.32) | EPHX1MIF | |
| SCHEMBL17964239 | 0.94 | MIF (0.32) | EPHX1MIF | |
| SCHEMBL19768571 | 0.90 | BTK (0.31) | EPHX1BTKMIFKMT2AL3MBTL1 | |
| SCHEMBL17964240 | 0.90 | BTK (0.31) | EPHX1BTKMIFKMT2AL3MBTL1 | |
| SCHEMBL17964282 | 0.87 | NOS1 (0.34) | EPHX1MIF | |
| SCHEMBL19768576 | 0.87 | NOS1 (0.34) | EPHX1MIF | |
| SCHEMBL17964249 | 0.85 | BTK (0.36) | EPHX1BTKMIFKMT2AL3MBTL1 | |
| SCHEMBL19768575 | 0.85 | BTK (0.36) | EPHX1BTKMIFKMT2AL3MBTL1 | |
| SCHEMBL19768595 | 0.85 | BTK (0.33) | BTKMIFKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190330138-A1 | SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-10-31 | — | — | US | disclosed |
| US-10392338-B2 | Spirofuranone compounds, derivatives thereof and processes for their preparation | Yissum Research Development Company, of The Hebrew University of Jerusalem Ltd. (IL) | 2019-08-27 | — | — | US | disclosed |
| US-20180016221-A1 | SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-01-18 | — | — | US | disclosed |
| EP-3250559-A1 | SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2017-12-06 | — | — | EP | disclosed |
| CN-107207455-A | Spirofuranone compounds, derivatives thereof and processes for their preparation | 耶路撒冷希伯来大学伊森姆研究发展公司 | 2017-09-26 | — | — | CN | disclosed |
| WO-2016120879-A1 | SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392338-B2 | Spirofuranone compounds, derivatives thereof and processes for their preparation | PKD1, PKD2, DHPS | EPHX1 1686/4885BTK 1187/4885MIF 2261/4885 |
| US-20180016221-A1 | SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION | PKD1, PKD2, DHPS | EPHX1 1686/4885BTK 1187/4885MIF 2261/4885 |
| US-20190330138-A1 | SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION | PKD1, PKD2, DHPS | EPHX1 1686/4885BTK 1187/4885MIF 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.